| Name | Mosapride Citrate Dihydrate |
|---|---|
| Synonyms | 5-Oxopentanoic acid - 4-amino-5-chloro-2-ethoxy-N-{[4-(4-fluorobe nzyl)-2-morpholinyl]methyl}benzamide (1:1) |
| Description | Mosapride (TAK-370) citrate dehydrate is a gastroprokinetic agent with 5-hydroxytryptamine4 receptor agonist activity and has been widely used in the research of a variety of gastrointestinal disorders. Mosapride citrate dihydrate potently inhibits Kv4.3 in a concentration-dependent manner with IC50 values of 15.2 μM[1]. Mosapride citrate dihydrateselectively stimulates upper GI motility in vivo[2]. |
|---|---|
| Related Catalog | |
| Target |
5-HT4 Receptor Kv4.3:15.2 μM (IC50) |
| In Vitro | Mosapride (0.3-30 μM) exhibits an inhibitory activity against Kv4.3 with an IC50 of 15.2 μM in a concentration-dependent manner. Mosapride also inhibits the open state of Kv4.3 currents during depolarization and accelerates the closed-state inactivation at subthreshold potentials[1]. |
| In Vivo | Mosapride (Intravenous injection;0.3-3 mg/kg) dose-dependently increases the antral motor activity in conscious dogs which indicates that mosapride selectively stimulates upper gastrointestinal motility[2]. Animal Model: Beagle dogs[2] Dosage: 0.3-3 mg/kg Administration: Intravenous injection; 0.3-3 mg/kg Result: Increased the antral motor activity dose-dependently in conscious dogs. |
| References |
| Melting Point | 112-114°C |
|---|---|
| Molecular Formula | C26H33ClFN3O6 |
| Molecular Weight | 538.00800 |
| Exact Mass | 537.20400 |
| PSA | 134.68000 |
| LogP | 4.62490 |
| Storage condition | 2-8°C |
| Symbol |
GHS05 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H318 |
| Precautionary Statements | P280-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi |
| Risk Phrases | 41 |
| Safety Phrases | 26 |
| RIDADR | NONH for all modes of transport |